Anemia Independently Linked to High Platelet Reactivity in PCI

This article originally appeared here.
Share this content:
Anemia Independently Linked to High Platelet Reactivity in PCI
Anemia Independently Linked to High Platelet Reactivity in PCI

THURSDAY, June 9, 2016 (HealthDay News) -- Anemia is independently associated with high platelet reactivity (HPR) and is associated with all-cause mortality and major bleeding after percutaneous coronary intervention with drug-eluting stents, according to a study published in the June 15 issue of The American Journal of Cardiology.

Gennaro Giustino, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues categorized patients from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study by the presence of anemia at baseline. A total of 8,413 patients were included in the study cohort, of whom 21.6 percent had anemia.

The researchers found that HPR was more prevalent in patients with anemia (58.3 versus 38.4 percent; P < 0.001); after multivariate adjustment the correlation persisted (adjusted odds ratio, 2.04; P < 0.0001). The two-year rates of major adverse cardiac events, major bleeding, and all-cause mortality were significantly higher for patients with anemia (all P < 0.0001); anemia was no longer associated with major adverse cardiovascular events but was still associated with all-cause mortality and major bleeding after adjustment for baseline clinical confounders, including HPR (adjusted hazard ratios, 1.61 and 1.42; both P < 0.0001).

"After percutaneous coronary intervention with drug-eluting stents, anemia at baseline was significantly associated with higher two-year hemorrhagic and mortality risk; conversely, its association with ischemic risk was attenuated after multivariate adjustment, including HPR," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, some of which sponsored the ADAPT-DES study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »